Herpes Virus - Revision history

Lazy at 08:29, 18 January 2025

2025-01-18T08:29:37Z

← Older revision		Revision as of 01:29, 18 January 2025
Line 22:		Line 22:
	virus injected directly into the tumor. Four were alive at the time of the report of the		virus injected directly into the tumor. Four were alive at the time of the report of the
	study, 14-24 months after the treatment (171).		study, 14-24 months after the treatment (171).
	}}		\|overview=The herpes virus, used in oncolytic virotherapy, has shown promise in treating recurrent glioblastomas by selectively targeting tumor cells, with studies indicating extended survival rates and minimal toxicity. Recent advancements involve engineered versions of the virus designed to maintain its anti-cancer properties while reducing neurological inflammation, demonstrating further potential in clinical trials.}}

69.163.248.232: Updated category= to treatment_category= in TreatmentInfo template

2024-11-12T18:47:40Z

Updated category= to treatment_category= in TreatmentInfo template

← Older revision		Revision as of 11:47, 12 November 2024
Line 3:		Line 3:
	{{TreatmentInfo		{{TreatmentInfo
	\|drug_name=Herpes Virus		\|drug_name=Herpes Virus
	\|~~category~~=Oncolytic virotherapy		\|treatment_category=Oncolytic virotherapy
	\|book_text=Another virus used in cancer therapy is a modified form of the herpes virus. Initial trials		\|book_text=Another virus used in cancer therapy is a modified form of the herpes virus. Initial trials
	used a retrovirus version, which infects only those cells dividing when the virus was		used a retrovirus version, which infects only those cells dividing when the virus was

Lazy: Created page with " {{TreatmentInfo |drug_name=Herpes Virus |category=Oncolytic virotherapy |book_text=Another virus used in cancer therapy is a modified form of the herpes virus. Initial trials used a retrovirus version, which infects only those cells dividing when the virus was infused. Subsequent trials have used an adenovirus version, which infects both dividing and non-dividing cells. Because the herpes virus can be lethal to the brain if allowed to proliferate, soon after the virus..."

2024-04-06T04:18:21Z

Created page with " {{TreatmentInfo |drug_name=Herpes Virus |category=Oncolytic virotherapy |book_text=Another virus used in cancer therapy is a modified form of the herpes virus. Initial trials used a retrovirus version, which infects only those cells dividing when the virus was infused. Subsequent trials have used an adenovirus version, which infects both dividing and non-dividing cells. Because the herpes virus can be lethal to the brain if allowed to proliferate, soon after the virus..."

New page

{{TreatmentInfo
|drug_name=Herpes Virus
|category=Oncolytic virotherapy
|book_text=Another virus used in cancer therapy is a modified form of the herpes virus. Initial trials
used a retrovirus version, which infects only those cells dividing when the virus was
infused. Subsequent trials have used an adenovirus version, which infects both dividing
and non-dividing cells. Because the herpes virus can be lethal to the brain if allowed to
proliferate, soon after the virus infusion patients receive ganciclovir, an effective
anti-herpes agent. In one study using this technique performed at Mt. Sinai Hospital in
New York (170), median survival of 12 patients with recurrent GBM tumors was 59 weeks
from the point of treatment, with 50% of the patients alive 12 months after the treatment.
The authors also reported the absence of toxicity from the treatment, which was a major
concern due to significant brain damage when the procedure was tested with monkeys.
Why the difference from the monkey study's results is unclear.

More recent research with the herpes virus has been focused on forms of the virus that
have been engineered to retain the anti-cancer effects of the virus but without its property
of producing neurological inflammation. The first use of this modified virus in a clinical
trial was in Glasgow, Scotland. Nine patients with recurrent glioblastomas received the
virus injected directly into the tumor. Four were alive at the time of the report of the
study, 14-24 months after the treatment (171).
}}